The therapeutic potential of ERBB3 inhibitors, such as AZD8931, demonstrates that TFE3-RCC cells lacking ARID2 are more sensitive to this treatment, providing promising directions for improving outcomes for patients with this aggressive cancer subtype. Here, ERBB3 is linked to cancer.